Lotus – OTCBB: LTUS – Stock Guru ProfileLotus Pharmaceuticals provides both traditional Chinese medicines and modern western medicines. This makes excellent business sense for the Chinese consumer who seeks treatment from both branches of medicine.Lotus is comprised of three divisions:
~Lotus owns ten drug stores in Beijing which distribute both modern medicine and traditional Chinese medicines;
~Lotus has a Research Development department developing drugs seven of which are in the pipeline waiting for approval by China’s equivalent of the FDA;
~Lotus manufactures the medicines developed by its Research and Development Department.
Lotus is an integrated pharmaceutical company led by an experienced team located in a country with a phenomenal GDP. Lotus attracts consumers of both modern medicine and traditional Chinese medicine to its pharmacies. Most consumers in China include traditional Chinese treatments with the inclusion of modern medicines in their treatment.
Chinese consumer often chose traditional treatments with Chinese herbal remedies for an overall well-being, especially in dealing with ill-defined, complex conditions such as chronic fatigue syndrome. Chinese medical practitioners typically spend more time chatting with patients about their problems than physicians. This creates closer doctor-patient relationships.
Chinese medicine relies on its prized herbs such as ginseng and lingzhi. A government household survey in 2002 found that about one-fifth of consultations sought every month were with Chinese medicine practitioners. And a Labour Department poll the following year found that of 2,769 people injured at work, one-third sought similar treatment.
Chinese medicine focuses on non-life-threatening, but debilitating conditions, such as arthritis, sleeping disorder and eczema. More hospitals now provide Chinese treatments at out-patient clinics. In March, Tung Wah Hospital introduced Chinese treatments to convalescing patients while Kwong Wah combined western and Chinese practices in some wards.
Dr. Liu Zhong Yi, the founder of Lotus Pharmaceuticals, Inc. understands the great appeal of combining traditional Chinese medicines with modern medicine. He earned his Master’s Degree in Beijing hospitals, after doing his undergraduate studies in his homeland of Inner Mongolia. Dr. Liu holds the title of Deputy Chief Physician, as a professional apothecary, in operating Lotus (Liang Fang) as one of China’s most innovative and fastest growing pharmaceutical companies.
As a researcher and medical student, Dr. Liu excelled in the development of many new drugs in wide use in China today. While working for the Chinese Government in 1992, he established the Research Center of Space Flight Biological Engineering Technology, and continued his renowned research related to incretion diseases. Four years later, entering the private sector and invigorated by burgeoning capitalism in China, Dr. Liu started his first pharmaceutical company in Beijing.
The year 1999 marked a landmark for Dr. Liu and his company by the introduction of VALSARTAN, China’s most effective and popular drug for the treatment of hypertension. During this same period, he commenced his hugely successful retail drug stores that now number 10 throughout Greater Beijing.
Lotus Pharmaceuticals has the retail distribution chain and the product pipeline for pharmaceuticals. They understand the Chinese consumer and provide them the medicines with which they are most comfortable.
Source: Lotus Pharmaceuticals and Chemical and Engineering News, March 2007
Lotus Pharmaceuticals, Inc.
7900 Glades Road, Suite 420
Boca Raton, Florida 33434
Phone: (877) 801-0344
Fax: (954) 337-2204 Email: info@lotuseast.com
Disclosure: Pentony Enterprises LLC was compensated $10,000 directly from the company for profile coverage. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site are suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company’s ability to obtain additional financing and the demand for the Company’s products. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations with regard to these forward-look ing statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the U.S. Securities and Exchange Commission (“SEC”).
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com.